<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial oral empiric antibiotics for outpatient treatment of pediatric community-acquired pneumonia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial oral empiric antibiotics for outpatient treatment of pediatric community-acquired pneumonia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Initial oral empiric antibiotics for outpatient treatment of pediatric community-acquired pneumonia</div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup><colgroup width="75%"></colgroup> <tbody> <tr> <td class="subtitle1">Age group</td> <td class="subtitle1">Empiric regimen</td> </tr> <tr> <td class="subtitle2_left" colspan="2">1 to 6 months</td> </tr> <tr> <td class="indent1">Bacterial (not <em>Chlamydia trachomatis</em>)</td> <td><strong>Infants &lt;3 to 6 months of age with suspected bacterial pneumonia should be hospitalized</strong></td> </tr> <tr> <td class="indent1"><em>C. trachomatis</em></td> <td>Refer to UpToDate topic on <em>C. trachomatis</em> infections in the newborn</td> </tr> <tr> <td class="subtitle2_left" colspan="2">6 months to 5 years</td> </tr> <tr> <td class="indent1" rowspan="13">Typical bacterial*</td> <td>Amoxicillin<sup>¶</sup> 90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day), <strong>or</strong></td> </tr> <tr> <td>Amoxicillin-clavulanate 90 mg/kg per day of the amoxicillin component in 2 or 3 divided doses (MAX 4 g/day amoxicillin component)</td> </tr> <tr> <td><strong>For children with mild reactions to a penicillin and no features of an IgE-mediated reaction</strong><sup>Δ</sup><strong>:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Amoxicillin 90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day), <strong>or</strong></li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Amoxicillin-clavulanate 90 mg/kg per day of the amoxicillin component in 2 or 3 divided doses (MAX 4 g/day amoxicillin component), <strong>or</strong></li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>A third-generation cephalosporin, such as cefdinir 14 mg/kg per day in 2 divided doses (MAX 600 mg/day) in communities with a low rate of pneumococcal resistance to penicillin</li> </ul> </td> </tr> <tr> <td><strong>For children with IgE-mediated or serious delayed reaction to a penicillin:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Levofloxacin<sup>◊</sup> 16 to 20 mg/kg per day in 2 divided doses (MAX 750 mg/day), <strong>or</strong></li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 1.8 g/day), <strong>or</strong></li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Linezolid 30 mg/kg per day in 3 divided doses (MAX 1.8 g/day)</li> </ul> </td> </tr> <tr> <td><strong>In communities with a high rate of pneumococcal resistance to penicillin:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Levofloxacin<sup>◊</sup> 16 to 20 mg/kg per day in 2 divided doses (MAX 750 mg/day), <strong>or</strong></li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Linezolid 30 mg/kg per day in 3 divided doses (MAX 1.8 g/day)</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">≥5 years</td> </tr> <tr> <td class="indent1" rowspan="6"><em>Mycoplasma pneumoniae</em> or <em>Chlamydia pneumoniae</em></td> <td>Azithromycin<sup>¶</sup> 10 mg/kg on day 1 followed by 5 mg/kg daily for 4 more days (MAX 500 mg on day 1 and 250 mg thereafter), <strong>or</strong></td> </tr> <tr> <td>Clarithromycin 15 mg/kg per day in 2 divided doses (MAX 1 g/day), <strong>or</strong></td> </tr> <tr> <td>Erythromycin 40 to 50 mg/kg per day in 4 divided doses (MAX 2 g/day as base, 3.2 g/day as ethylsuccinate), <strong>or</strong></td> </tr> <tr> <td>Doxycycline 4 mg/kg per day in 2 divided doses (MAX 200 mg/day), <strong>or</strong></td> </tr> <tr> <td>Levofloxacin<sup>◊</sup> 8 to 10 mg/kg once daily for children 5 to 16 years (MAX 500 mg/day); 500 mg once daily for children ≥16 years, <strong>or</strong></td> </tr> <tr> <td>Moxifloxacin<sup>◊</sup><sup>§</sup> 400 mg once daily (≥18 years)</td> </tr> <tr> <td class="indent1" rowspan="11">Typical bacterial*</td> <td>Amoxicillin<sup>¶</sup> 90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day)</td> </tr> <tr> <td><strong>For children with mild reactions to a penicillin and no features of an IgE-mediated reaction</strong><sup>Δ</sup><strong>:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Amoxicillin 90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day), <strong>or</strong></li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>A third-generation cephalosporin, such as cefdinir 14 mg/kg per day in 2 divided doses (MAX 600 mg/day)</li> </ul> </td> </tr> <tr> <td><strong>For children with IgE-mediated or serious delayed reaction to a penicillin:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Levofloxacin<sup>◊</sup> 8 to 10 mg/kg once daily for children 5 to 16 years (MAX 750 mg/day); 750 mg once daily for children ≥16 years, <strong>or</strong></li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 1.8 g/day), <strong>or</strong></li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Linezolid 30 mg/kg per day in 3 divided doses (MAX 1.8 g/day) for children &lt;12 years; 20 mg/kg per day divided in 2 doses (MAX 1.2 g/day) for children ≥12 years</li> </ul> </td> </tr> <tr> <td><strong>In communities with a high rate of pneumococcal resistance to penicillin:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Levofloxacin<sup>◊</sup> 8 to 10 mg/kg once daily for children 5 to 16 years (MAX 750 mg/day); 750 mg once daily for children ≥16 years, <strong>or</strong></li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Linezolid 30 mg/kg per day divided in 3 doses (MAX 1.8 g/day) for children &lt;12 years; 20 mg/kg per day divided in 2 doses (MAX 1.2 g/day) for children ≥12 years</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Aspiration pneumonia</td> </tr> <tr> <td class="indent1" rowspan="6">Community-acquired</td> <td>Amoxicillin-clavulanate 40 to 50 mg/kg per day in 2 or 3 divided doses (MAX 1.75 g/day amoxicillin component)</td> </tr> <tr> <td><strong>For children with mild reactions to a penicillin and no features of an IgE-mediated reaction</strong><sup>Δ</sup><strong>:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Amoxicillin-clavulanate 40 to 50 mg/kg per day in 2 or 3 divided doses (MAX 1.75 g/day amoxicillin component)</li> </ul> </td> </tr> <tr> <td><strong>For children with IgE-mediated or serious delayed reaction to amoxicillin:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Clindamycin 30 to 40 mg/kg per day divided in 3 or 4 doses (MAX 1.8 g/day)</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Moxifloxacin<sup>◊</sup> 400 mg once daily (for ≥18 years)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>MAX: maximum; IgE: immunoglobulin E.</p>
<p>* For the infant or child who is suspected to have bacterial community-acquired pneumonia and is unable to tolerate liquids at the time of presentation, a single initial dose of ceftriaxone (50 to 75 mg/kg) may be administered intramuscularly or intravenously before starting oral antibiotics.</p>
<p>¶ Preferred agent.</p>
<p>Δ The choice is individualized according to the drug allergy history and the ability to safely conduct an oral challenge if necessary. Refer to UpToDate content on penicillin allergy.</p>
<p>◊ In the United States, fluoroquinolones (eg, levofloxacin and moxifloxacin) are approved by the US Food and Drug Administration for community-acquired pneumonia for patients ≥18 years of age. However, they may be used in younger children if other antibiotics are inappropriate (eg, due to hypersensitivity or local antimicrobial resistance patterns).</p>
§ Also covers typical bacterial pathogens.</div><div class="graphic_reference">Data from:
<ol>
<li>McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.</li>
<li>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.</li>
<li>American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.876.</li>
</ol></div><div id="graphicVersion">Graphic 80561 Version 28.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
